2024
A review on polyamines as promising next-generation neuroprotective and anti-aging therapy
Arthur R, Jamwal S, Kumar P. A review on polyamines as promising next-generation neuroprotective and anti-aging therapy. European Journal Of Pharmacology 2024, 978: 176804. PMID: 38950837, DOI: 10.1016/j.ejphar.2024.176804.Peer-Reviewed Original ResearchCognitive dysfunctionNeurodegenerative disordersRegulation of gene expressionProgressive degeneration of neuronsProgrammed cell deathDegeneration of neuronsSymptomatic therapyPharmacological strategiesAnti-oxidative effectsAnti-aging therapyAverage ageProgressive degenerationNeuroprotective effectsLocomotor abnormalitiesIon channelsCell deathBiochemical activityGene expressionPopulation average ageTherapyMolecular mechanismsDisordersPolyamine supplementationDysfunctionAnti-aging effectsDopamine Transporter Deficiency Syndrome (DTDS)
Jamwal S, Gautam A. Dopamine Transporter Deficiency Syndrome (DTDS). 2024, 1-4. DOI: 10.1007/978-3-319-66816-1_452-1.Peer-Reviewed Original ResearchDopamine transporter deficiency syndromeDopamine transporterMovement disordersHuman dopamine transporterSLC6A3 geneBehavioral symptomsAmbiguous eventsEarly adolescenceSlow speechDisordersHyperkinetic movementsSLC6A3Choreiform movementsAdolescentsEarly childhoodAssociated with poor outcomesLater onsetHypokinetic movementsAffected individualsNon-specific symptomsSymptomsDevelopmental targetsEarly-onsetResting tremorRecurrent movement disordersNutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain
Soni D, Jamwal S, Chawla R, Singh S, Singh D, Singh T, Khurana N, Kanwal A, Dureja H, Patil U, Singh R, Kumar P. Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain. Food Reviews International 2024, 40: 3079-3102. DOI: 10.1080/87559129.2024.2337766.Peer-Reviewed Original ResearchPre-clinicalGut-brain axisProtein ubiquitinationParkinson's diseaseMitochondrial dysfunctionSignaling pathwayMolecular mechanismsRelieve PD symptomsSymptoms of PDClinical trialsHealth benefits of nutraceuticalsBenefits of nutraceuticalsCustomized therapyClinical aspectsExpression of PDMediterranean dietNeurotransmitter imbalanceNeuroprotective mechanismsNeuroprotective potentialOxidative stressDiseasePD symptomsHealth benefitsSymptomsUbiquitin
2023
Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats
Yedke N, Upadhayay S, Singh R, Jamwal S, Ahmad S, Kumar P. Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats. Biomolecules 2023, 13: 1667. PMID: 38002349, PMCID: PMC10669047, DOI: 10.3390/biom13111667.Peer-Reviewed Original ResearchConceptsBCG vaccineTardive dyskinesiaOrofacial dyskinesiaNeurotransmitter levelsBacillus Calmette-Guérin (BCG) vaccineFirst-generation antipsychotic drugsManagement of TDOxidative stressLevels of HVACalmette-Guérin vaccineHyperkinetic movement disordersMajor pathophysiological mechanismsPro-apoptotic markersLong-term useBCG treatmentNeuroprotective effectsNeurochemical alterationsOrofacial dysfunctionPathophysiological mechanismsAntipsychotic medicationNeuromodulatory propertiesSuppress inflammationSingle administrationAntipsychotic drugsHaloperidol injectionAge-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain
Jamwal S, Blackburn J, Elsworth J. Age-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain. Biology Of Sex Differences 2023, 14: 65. PMID: 37770961, PMCID: PMC10540392, DOI: 10.1186/s13293-023-00551-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraSex-dependent expressionPrimate brainAdult male monkeysCerebrospinal fluidMale monkeysPeroxisome proliferator-activated receptor gamma agonistProliferator-activated receptor gamma agonistsEffect of pioglitazoneWeeks of treatmentReceptor gamma agonistsGreater expressionAdult female monkeysNonhuman primate brainNovel neuroprotective treatmentAfrican green monkeysSex-based differencesOral pioglitazoneNeuroprotective treatmentPIO treatmentRisk factorsCNS disordersGamma agonistsPreclinical studiesParkinson's diseaseAnimal models of Huntington’s disease and their applicability to novel drug discovery and development
Upadhayay S, Jamwal S, Kumar P. Animal models of Huntington’s disease and their applicability to novel drug discovery and development. Expert Opinion On Drug Discovery 2023, 18: 527-538. PMID: 37042034, DOI: 10.1080/17460441.2023.2201493.Peer-Reviewed Original ResearchConceptsHD animal modelsAnimal modelsHuntington's diseaseNon-motor symptomsProgressive neurodegenerative disorderDrug therapyDisease progressionPreclinical phaseLoss of functionNeurodegenerative disordersClinical phaseDrug discoveryDiseaseNovel drug discoveryHuntingtin geneToxic gainCAG trinucleotide repeatDrugsProgressionHD geneEnormous progressionAn Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A, Chandolia P, Kaur P, Kumar M, Koshal P, Jamwal S, Kumar P. An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Research 2023, 48: 1631-1647. PMID: 36738367, DOI: 10.1007/s11064-023-03868-1.Peer-Reviewed Original ResearchConceptsMedium spiny neuronsAnimal modelsGABAergic medium spiny neuronsDisease modelsKey clinical manifestationsHuntington's disease modelsPathogenesis of diseaseWeb of ScienceClinical manifestationsPathophysiological mechanismsSpiny neuronsPreclinical studiesMotor impairmentLike symptomsTherapeutic targetExperimental animalsExcessive productionHuntington's diseaseOxidative stressDiseasePathogenic conditionsDrug discoveryMitochondrial functionFree radicalsNeurotoxin
2022
miRNA‐encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers
Dey A, Yousefiasl S, Kumar A, Moghaddam F, Rahimmanesh I, Samandari M, Jamwal S, Maleki A, Mohammadi A, Rabiee N, Paiva‐Santos A, Tamayol A, Sharifi E, Makvandi P. miRNA‐encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers. Bioengineering & Translational Medicine 2022, 8: e10343. PMID: 36684081, PMCID: PMC9842058, DOI: 10.1002/btm2.10343.Peer-Reviewed Original Research
2021
Expression of PON2 isoforms varies among brain regions in male and female African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Expression of PON2 isoforms varies among brain regions in male and female African green monkeys. Free Radical Biology And Medicine 2021, 178: 215-218. PMID: 34890766, PMCID: PMC8760629, DOI: 10.1016/j.freeradbiomed.2021.12.005.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParkinson's diseaseBrain regionsParaoxonase 2Different brain regionsFemale monkeysGreen monkeysPON2 expressionOxidative stress-related neurodegenerative disordersFemale African green monkeysNeurodegenerative disordersMale African green monkeysOxidative stressPON2 protein expressionAnti-inflammatory propertiesExpression levelsSignificant differencesBrain tissue samplesDorsolateral prefrontal cortexNeuroprotective strategiesWestern blotting techniquesDopaminergic neuronsPON2 proteinPrimate brainProtective rolePioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brainRole of vitamins and minerals as immunity boosters in COVID-19
Kumar P, Kumar M, Bedi O, Gupta M, Kumar S, Jaiswal G, Rahi V, Yedke NG, Bijalwan A, Sharma S, Jamwal S. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology 2021, 29: 1001-1016. PMID: 34110533, PMCID: PMC8190991, DOI: 10.1007/s10787-021-00826-7.Peer-Reviewed Original ResearchConceptsRole of vitaminsCOVID-19SARS-CoV-2 COVID-19Immune systemSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Multiple inflammatory responsesSyndrome coronavirus 2Chronic infectious diseaseCOVID-19 infectionBalanced nutritional dietUsage of vitaminCoronavirus 2Inflammatory responsePlasma concentrationsImmune stateMortality rateVitamin AImmunity boosterMeaningful therapiesNarrative reviewSystem strengtheningCoronavirus diseaseSex-based disparity in paraoxonase-2 expression in the brains of African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys. Free Radical Biology And Medicine 2021, 167: 201-204. PMID: 33722626, PMCID: PMC8096713, DOI: 10.1016/j.freeradbiomed.2021.03.003.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParaoxonase 2Parkinson's diseaseBrain regionsGreen monkeysOxidative stressReactive oxygen speciesAnti-inflammatory propertiesSex-based disparitiesParaoxonase-2 expressionDifferent brain regionsNigrostriatal systemPON2 expressionDevelopment of therapeuticsNeurodegenerative disordersDiseaseProtein levelsROS levelsLower ROS levelsMitochondrial performanceSex-based variationDisordersMonkeysOxygen speciesMalesNeuroprotection through G-CSF: recent advances and future viewpoints
Rahi V, Jamwal S, Kumar P. Neuroprotection through G-CSF: recent advances and future viewpoints. Pharmacological Reports 2021, 73: 372-385. PMID: 33389706, DOI: 10.1007/s43440-020-00201-3.Peer-Reviewed Original ResearchConceptsGranulocyte-colony stimulating factorNeutrophilic granulocyte lineageNumerous cell typesJAK/STATG-CSF receptorPI3K/AktInhibition of apoptosisTransduction pathwaysHaemopoietic stem cellsMAP kinaseNeuronal differentiationHematopoietic stemCell typesGranulocyte lineageNeurological disordersStem cellsProgenitor cellsRecent pre-clinical studiesHematopoietic growth factorsAttractive targetChemotherapy-associated neutropeniaStimulation of neurogenesisObserved neuroprotective effectsDifferentiationPre-clinical studiesChapter 5 Protocols in apoptosis identification and affirmation
Jamwal S, Kumar P, Kakkar V, Kumari P, Chahal S. Chapter 5 Protocols in apoptosis identification and affirmation. 2021, 127-152. DOI: 10.1016/b978-0-12-815762-6.00005-6.Peer-Reviewed Original ResearchCell deathApoptosis researchDeath-signaling pathwaysCell cycle mechanismsPathways of introductionRegulatory genesMembrane blebbingCell divisionChromatin condensationCell cycleApoptotic bodiesCell shrinkageRemoval of cellsNormal homeostasisApoptosisSpecific activationNeurodegenerative diseasesPathwayApoptosis quantificationCycle mechanismIndividual morphological featuresDiseased conditionsBiomedical researchDisease statesDrug development
2020
Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder. Molecular Biology Reports 2020, 47: 9895-9912. PMID: 33263931, DOI: 10.1007/s11033-020-06033-x.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDocosahexaenoic acidAlzheimer's diseaseArachidonic acidLipid mediatorsAnti-inflammatory actionAppropriate therapeutic optionPro-inflammatory eicosanoidsProduction of eicosanoidsResolution of inflammationRole of AACOX-2 enzymeLOX pathwayNeuroinflammatory responseNeuroinflammatory eventsTherapeutic optionsAD patientsCytokine secretionEpidemiological studiesLeukocyte traffickingNF-κBEicosanoid productionBrain disordersNeurological disordersCyclooxygenasePPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising targetGene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHDAn updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sciences 2020, 257: 118105. PMID: 32687917, PMCID: PMC7366108, DOI: 10.1016/j.lfs.2020.118105.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsSARS-CoV-2Secondary complicationsPathogenic SARS-CoV-2Hospitalized COVID-19 patientsRecovered COVID-19 patientsCOVID-19Brief clinical updatesNew SARS-CoV-2 virusCOVID-19 pathogenesisACE-2Broad-spectrum antiviral drugsCOVID-19 infectionCoronavirus disease 2019Vaccines/drugsSARS-CoV-2 virusHepatic complicationsViral burdenConvalescent plasmaClinical updateAngiotensin IIImmune damageEpidemiological featuresClinical trialsDisease 2019Protective Effect of Hemin Against Experimental Chronic Fatigue Syndrome in Mice: Possible Role of Neurotransmitters
Thakur V, Jamwal S, Kumar M, Rahi V, Kumar P. Protective Effect of Hemin Against Experimental Chronic Fatigue Syndrome in Mice: Possible Role of Neurotransmitters. Neurotoxicity Research 2020, 38: 359-369. PMID: 32506340, DOI: 10.1007/s12640-020-00231-y.Peer-Reviewed Original ResearchMeSH Keywords3,4-Dihydroxyphenylacetic AcidAnimalsAnxietyBehavior, AnimalBrainDisease Models, AnimalDopamineElectron Transport Complex IElectron Transport Complex IIElevated Plus Maze TestEnzyme InhibitorsFatigue Syndrome, ChronicGlutathioneHand StrengthHeme Oxygenase-1HeminHomovanillic AcidHydroxyindoleacetic AcidLipid PeroxidationLocomotionMetalloporphyrinsMiceMitochondriaNeurotransmitter AgentsNitritesNorepinephrineProtoporphyrinsSerotoninConceptsChronic fatigue syndromeMitochondrial complex dysfunctionFatigue syndromeProtective effectComplex dysfunctionMale albino miceAnxiety-like behaviorFatigue-like behaviorAntifatigue effectNeurotransmitter alterationsCommon symptomsPresent studyNeurotransmitter levelsSwimming testAlbino miceExperimental miceImmobility periodEnzyme inhibitorsProtective roleCognitive impairmentLocomotor activityBehavioral testsSwimming sessionBiochemical parametersBiochemical alterations
2019
P2‐164: NEUROPROTECTIVE MECHANISM OF SPERMIDINE ALONE AND IN COMBINATION WITH NITRIC OXIDE PATHWAY MODULATORS AGAINST 3‐NP‐INDUCED BEHAVIORAL, BIOCHEMICAL AND NEUROTRANSMITTER ALTERATIONS IN RAT STRIATUM
Jamwal S. P2‐164: NEUROPROTECTIVE MECHANISM OF SPERMIDINE ALONE AND IN COMBINATION WITH NITRIC OXIDE PATHWAY MODULATORS AGAINST 3‐NP‐INDUCED BEHAVIORAL, BIOCHEMICAL AND NEUROTRANSMITTER ALTERATIONS IN RAT STRIATUM. Alzheimer's & Dementia 2019, 15: p638-p638. DOI: 10.1016/j.jalz.2019.06.2571.Peer-Reviewed Original Research